What factors affect survival in the treatment of ALK-positive NSCLC with brigatinib?

Brigatinib (Brigatinib) is a therapeutic drug for ALK-positive non-small cell lung cancer (NSCLC). Its efficacy and patient survival are affected by multiple factors.

Clinical studies have shown that brigatinib (Brigatinib) can significantly prolong the progression-free survival (PFS) of ALKpositive NSCLC patients. Data from the ALTA-1L trial showed that the median progression-free survival was significantly longer in the brigatinib (brigatinib) treatment group compared with the control group, highlighting the significant effect of brigatinib (brigatinib) in controlling tumor progression. In actual clinical applications, many patients' conditions have been effectively controlled and their survival has been significantly prolonged after receiving treatment with brigatinib.

However, individual patient differences have an important impact on survival. These factors include the patient's age, overall health, tumor stage, presence of comorbidities, and tolerance to brigatinib. Generally, patients with good health, early-stage tumors, and no serious comorbidities are likely to survive longer. Because the effectiveness and tolerability of brigatinib varies among patients, the drug itself cannot be used to predict patient survival.

Although brigatinib shows good efficacy in many patients, some patients may develop resistance to the drug over time. This resistance may affect the long-term effects of the drug and thus have an impact on survival. In addition, Brigatinib may also cause some side effects, such as interstitial lung disease (ILD) or severe hypertension. These side effects need to be managed in time, otherwise they may have an adverse impact on the patient's overall health and survival.

In order to improve the treatment effect and prolong survival, brigatinib (brigatinib) is usually used in combination with other treatments (such as chemotherapy, immunotherapy, etc.). This comprehensive treatment regimen can more comprehensively control tumors and effectively deal with possible drug resistance issues, thereby helping to improve the overall survival of patients.